AMPA Receptor Antagonists
| Cat. No. | 产品名称/活性 |
|---|---|
| 0190 | CNQX |
| Potent and selective non-NMDA iGluR antagonist | |
| 1045 | CNQX disodium salt |
| Potent non-NMDA iGluR antagonist; more water soluble form of CNQX (Cat. No. 0190) | |
| 2932 | CP 465022 hydrochloride |
| Selective and non-competitive AMPA antagonist | |
| 0189 | DNQX |
| Selective non-NMDA iGluR antagonist | |
| 2312 | DNQX disodium salt |
| Selective non-NMDA iGluR antagonist; water-soluble salt of DNQX (Cat. No. 0189) | |
| 0845 | Evans Blue tetrasodium salt |
| Non-NMDA iGluR antagonist; P2X antagonist; also inhibits L-glutamate uptake into synaptic vesicles | |
| 1454 | GYKI 52466 dihydrochloride |
| Selective non-competitive AMPA antagonist | |
| 2555 | GYKI 53655 hydrochloride |
| Non-competitive non-NMDA iGluR antagonist | |
| 2766 | Naspm trihydrochloride |
| Ca2+-permeable AMPA antagonist | |
| 0373 | NBQX |
| Potent AMPA antagonist; more selective than CNQX (Cat. No. 0190) | |
| 1044 | NBQX disodium salt |
| Potent AMPA antagonist; more water soluble form of NBQX (Cat. No. 0373) | |
| 5032 | Talampanel |
| Non-competitive non-NMDA iGluR antagonist | |
| 2345 | ZK 200775 |
| Competitive non-NMDA iGluR antagonist |
Addiction Life Science Poster
Written by Prof David Nutt, this poster summarizes the brain circuits and neurotransmitter systems that are affected by the main classes of addictive drugs.
Request copyDownload PDFAlzheimer's Life Science Poster
Written by Dimitra Sokolova and Soyon Hong
Our Alzheimer's disease poster summarizes the genetic, molecular and cellular changes observed in the progression of this neurodegenerative disease.
Request copyDownload PDFDepression Life Science Poster
Written by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDFParkinson's Life Science Poster
Written by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF